Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anil Abeyewickreme

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
BMJ Case Reports|July 5, 2012
Progression of coronary disease in a Behcet's patient in remissionAnil Abeyewickreme, Anil Ramoutar, Alamgir Kabir
Integrative Biology : Quantitative Biosciences From Nano to Macro|December 22, 2009
Bio-electrospraying embryonic stem cells: interrogating cellular viability and pluripotencyAnil Abeyewickreme, Albert Kwok, Jean R McEwan, et al.
Journal of Neurology|June 29, 2026
Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS studyRiley Bove, Dawn Langdon, Maciej Maciejowski, et al.
Multiple Sclerosis and Related Disorders|December 11, 2025
Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosisStephen L Hauser, Mark S Freedman, Jin Nakahara, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
BMJ Case Reports|July 5, 2012
Progression of coronary disease in a Behcet's patient in remissionAnil Abeyewickreme, Anil Ramoutar, Alamgir Kabir
Integrative Biology : Quantitative Biosciences From Nano to Macro|December 22, 2009
Bio-electrospraying embryonic stem cells: interrogating cellular viability and pluripotencyAnil Abeyewickreme, Albert Kwok, Jean R McEwan, et al.
Journal of Neurology|June 29, 2026
Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS studyRiley Bove, Dawn Langdon, Maciej Maciejowski, et al.
Multiple Sclerosis and Related Disorders|December 11, 2025
Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosisStephen L Hauser, Mark S Freedman, Jin Nakahara, et al.
Pageof 1